about
Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.Exam preparation course in obstetrics and gynecology for the German Medical State Examination: proof of concept and implications for the recruitment of future residents.Inter-rater reliability and double reading analysis of an automated three-dimensional breast ultrasound system: comparison of two independent examiners.Development and psychometric validation of a shorter version of the Breast Cancer Treatment Outcome Scale (BCTOS-12).Is Mastectomy Oncologically Safer than Breast-Conserving Treatment in Early Breast Cancer?Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trialWhich patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer SubtypeEfficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgeryOncoplastic breast-conserving surgery: More relevant than ever? Results of a survey among breast surgeonsEvolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort StudyNon-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohortChanges of breast and axillary surgery patterns in patients with primary breast cancer during the past decadeCut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast CancerTime Trends of Neoadjuvant Chemotherapy for Early Breast Cancer
P50
Q37385681-FCA7BC80-1234-46E3-8F94-C9B99B0BE63EQ38809616-81E1AFD7-155F-45C1-A90B-E704FDBD9F0DQ40106637-B9F1859E-2A19-46F2-A9E3-46929CFC71CFQ49719784-B36D4C18-4AC3-40E0-B656-BFEAA515B271Q49885178-7110F510-239E-4712-907E-3ABCC231488AQ53220263-76F39B6C-B02A-496F-92EE-19C211DF560CQ56518072-C77BA1E4-8308-4A20-BA61-EADF7F8DC052Q57470519-9F41994F-B59E-40E0-9688-DF902496D0A4Q90665395-A3B0AF4F-D043-46C1-AD89-5F6CFBC35D27Q90951749-880A5AEC-30E8-4157-9EC6-67794C8AEB6DQ91103818-3F3BE691-FE3F-44F5-B75F-1FF8BB4BF3B0Q91720791-AA86D879-A0CB-4671-BEFE-3FD5A522E0F3Q93006350-2F0E9F32-1300-4BB6-A9A5-39ADF4CC7F28Q93383205-2795F546-1D8C-4CF3-BD4B-234AEBF94735Q94449288-595AA14F-CF1B-47E7-8D4A-7AF86637EB92Q95939415-A0E2457B-7A6C-4983-A758-96AE4CD716B1
P50
description
researcher ORCID ID = 0000-0002-9693-2667
@en
wetenschapper
@nl
name
Fabian Riedel
@ast
Fabian Riedel
@de
Fabian Riedel
@en
Fabian Riedel
@es
Fabian Riedel
@nl
type
label
Fabian Riedel
@ast
Fabian Riedel
@de
Fabian Riedel
@en
Fabian Riedel
@es
Fabian Riedel
@nl
prefLabel
Fabian Riedel
@ast
Fabian Riedel
@de
Fabian Riedel
@en
Fabian Riedel
@es
Fabian Riedel
@nl
P227
P101
P1153
57038354200
P19
P21
P214
848147786741468220001
P227
1117048381
P31
P496
0000-0002-9693-2667
P569
1987-01-01T00:00:00Z
P7859
viaf-848147786741468220001